Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Daiichi Sankyo Ltd ADR (OP: DSNKY )

35.86 +0.38 (+1.07%)
Streaming Delayed Price Updated: 3:59 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 63,825
Open 35.85
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 35.48
Today's Range 35.49 - 36.84
52wk Range 23.72 - 37.57
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
DSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q3 2023
Daiichi Sankyo Co just reported results for the third quarter of 2023. 
Via InvestorPlace
Double Good News For AstraZeneca's Breast Cancer Drugs
Results from AstraZeneca's Enhertu trial vs. chemotherapy in HR-positive, HER2-low metastatic breast cancer. 
Via Benzinga

Performance

YTD
+32.37%
+32.37%
1 Month
+14.88%
+14.88%
3 Month
+17.46%
+17.46%
6 Month
+29.04%
+29.04%
1 Year
+4.34%
+4.34%

More News

Read More
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
Via Benzinga
Exposures Product Safety
What's Going On With Pfizer Stock Today?
Via Benzinga
Why Pharmaceutical Company Esperion Therapeutics Shares Are Diving Today
Via Benzinga
Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact
Via Benzinga
Daiichi Sankyo Seeks Approval In Japan For Its mRNA-Based COVID-19 Vaccine
Via Benzinga
This Cancer Focused Stock Has 60% Potential Upside, Bullish Analyst Says
Via Benzinga
Japan Emerges As Promising 2024 Investment Destination: 3 Stocks To Consider
Via Benzinga
Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?
Via The Motley Fool
Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
Via Benzinga
AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials
Via Benzinga
FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt
Via Benzinga
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
Via Benzinga
AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
Via Benzinga
Japanese Pharma Company Sponsors Australian Start Up In Development Of Non-Hallucinogenic Medicines
Via Benzinga
AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
Via Benzinga
Is Gilead Sciences a Good Stock to Buy Now?
Via The Motley Fool
AstraZeneca’s Next “Wonder Drug”
Via Talk Markets
AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs
Via Benzinga
AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients
Via Benzinga
European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs
Via Benzinga
With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma
Via Benzinga
3 Top Stocks to Invest In Right Now
Via InvestorPlace
Seagen Suffers Loss In Arbitration Dispute Over ADC Technology
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.